As of 2026-09-14, the EV/EBITDA ratio of Turning Point Therapeutics Inc (TPTX) is -10.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TPTX's latest enterprise value is 3,484.99 mil USD. TPTX's TTM EBITDA according to its financial statements is -340.81 mil USD. Dividing these 2 quantities gives us the above TPTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 22.2x | 14.2x |
| Forward P/E multiples | 18.7x - 29.1x | 20.5x |
| Fair Price | (122.48) - (146.50) | (113.39) |
| Upside | -261.1% - -292.7% | -249.2% |
| Date | EV/EBITDA |